News Archive

2022

CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients

 

CryoTherapeutics, focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks, announces today that it has received additional funding of € 12.3 million.